Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFIRINOX and SBRT in Resectable Pancreatic Cancer
NCT05181605Phase 3Unknown
- Sponsor
- INIBICA
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, folinic acid, irinotecan and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by INIBICA. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05181605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181605.